
NanoSphere Announces Anti-Aging Product Using Nano-Sized Particles of Hyaluronic Acid

written by Raj Shah | January 17, 2019



January 17, 2019 (<u>Source</u>) - <u>NanoSphere Health Sciences, Inc.</u> (CSE: NSHS) (OTC: NSHSF) announced today it has developed an anti-aging product combining Hyaluronic Acid (HA) with the Company's patented Nanosphere Delivery System[™].

NanoSphere is best known for developing cannabis and CBD products that are delivered via the Company's patented delivery system. While that enterprise continues to grow, this is NanoSphere's first product for the cosmeceutical industry.

Hyaluronic Acid (HA) is a large linear polymer that occurs naturally in the human body and decreases with age. HA is commonly used to remoisturize dry skin, eliminate wrinkles and treat skin aging as a cosmeceutical. HA is also injected as a dermal filler by aesthetic surgeons and can be applied to wounds to accelerate healing.

The new product now being tested by NanoSphere is intended to greatly improve the results of Hyaluronic Acid for treating skin anti-aging without the need for injection.

NanoSphere is also testing the prototype's effectiveness for treating joint stiffness and arthritic pain. Currently high molecular weight HA is injected into joints by orthopedic surgeons to reduce pain and improve mobility associated with degenerative joint disorders. By contrast, topically applied NanoSphere HA is optimized for penetration into the skin, joints and wounds, delivering greater activity and sustained effects via NanoSphere's patented nanoparticle delivery system.

"The main issue with Hyaluronic Acid as an anti-aging compound is that the polymer molecules are too large to penetrate through skin in typical preparations, so It could only be highly effective in therapy when administered through injection or broken into shorter fragments that may cause inflammation," explains NanoSphere Chief Science Officer Dr. Richard Kaufman. "Our process encapsulates pharmaceutical grade HA of higher molecular weights in flexible, deformable patented NanoSphere lipid nanoparticles. The result is a viscoelastic NanoGel containing flexible nanoparticles of Hyaluronic Acid capable of penetrating the human skin, aiding delivery to target sites where it is most effective."

Kaufman says the result is not exactly the same as HA dermal fillers and joint treatments delivered by hypodermic needles, which may show dramatic results almost immediately. However, the NanoSphere HA solution over a period of weeks can show some remarkable benefits, says NanoSphere CEO Robert Sutton.

"This research represents a potential breakthrough that will make anti-aging, joint mobility, and wound healing treatments more affordable and available to the general population," Sutton said. "We are still studying its long-term effectiveness, but initial study results are very promising."

Kaufman says the NanoSphere product is different from current cosmetic HA treatments. NanoSphere HA is able to deliver Hyaluronic Acid into the epidermis and the joints with high molecular weights greater than 800,000 Daltons, similar to what the human body forms naturally. As well, the NanoSphere lipid nanoparticles are 'elastic' and were shown to better penetrate the skin than rigid nanoparticles.

Sutton says NanoSphere HA is currently going through internal testing and clinical trials and will be offered for sale only when that process is complete.

On behalf of the Board

Robert Sutton, Chairman and CEO

NanoSphere's Commitment to Licensing IP

NanoSphere launched its IP licensing program in 2015 and is entertaining several licensing opportunities via a rigorous evaluation process. For more information about NanoSphere's licensing program, please visit: https://www.nanospherehealth.com/licensing/

About NanoSphere

NanoSphere Health Sciences, Inc. is a biotechnology firm specializing in the creation of the patented NanoSphere Delivery System™, a revolutionary platform using nanotechnology in the biodelivery of supplements, nutraceuticals and over-the-counter medications for the cannabis, pharmaceutical and animal health industries, and beyond. Nanosphere's 'Evolve Formulas' line of products offer the world's first and only scientifically proven nanoparticle delivery system in cannabis. For more information on Evolve Formulas, visit <u>https://www.evolveformulas.com/</u>. Follow us on_<u>Facebook</u>, <u>Instagram</u> and <u>Twitter</u>.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

Forward Looking Statement Caution

This news release includes forward looking statements that are subject to assumptions, risks and uncertainties. Statements in this news release which are not purely historical are forward looking statements, including without limitation any statements concerning the Company's intentions, plans, estimates, expectations or beliefs regarding the future. Although the Company believes that any forward looking statements in this news release are reasonable, there can be no assurance that any such forward looking statements will prove to be accurate. The Company cautions readers that all forward looking statements, including without limitation those relating to the Company's future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward looking statements. Readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance on forward looking statements. Any forward looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward looking statements, or to update the reasons why actual events or results could or do differ from those projected in the forward looking statements, whether as a result of new information, future events or otherwise.